Home > Legislation > 117th Congress > H.R.4369

H.R.4369 - National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021117th Congress (2021-2022) |

Bill

Hide Overview
Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] (Introduced 07/06/2021)
Committees: House - Energy and Commerce | Senate - Health, Education, Labor, and Pensions
Committee Reports: H. Rept. 117-151
Latest Action: Senate - 10/20/2021 Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.  (All Actions)
Roll Call Votes: There has been 1 roll call vote

Tracker:

This bill has the status Passed House

Here are the steps for Status of Legislation:

  1. Introduced
  2. Passed House
  3. Passed Senate
  4. To President
  5. Became Law

More on This Bill

  • Constitutional Authority Statement
  • CBO Cost Estimates [1]

Subject — Policy Area:

Give Feedback on This Bill

  • Contact Your Member

Summary: H.R.4369 — 117th Congress (2021-2022)All Information (Except Text)

Bill summaries are authored by CRS.

Shown Here:
Passed House (10/19/2021)

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)